Eupraxia Pharmaceuticals (EPRX) investor relations material

Growth outlook and financial position

• Poised for significant growth in 2026 with compelling clinical data from the RESOLVE trial in Eosinophilic Esophagitis (EoE).

• Over $140M in cash and short-term assets as of March 31, 2026, supporting operations into H2 2028 and beyond key catalysts.

• Quarterly readouts of Phase 1b/2a data and topline Phase 2b trial data expected in Q4 2026.

• Initiation of a clinical trial in an additional indication planned for H2 2026.

• Market capitalization of $497 million as of May 12, 2026, with share price at $7.61.

EP-104GI and Diffusphere™ platform

• EP-104GI targets EoE, a disease projected to affect over one million people in the US by 2030.

• Diffusphere™ platform enables controlled, localized, and durable drug delivery, minimizing systemic exposure.

• EP-104GI is designed for annual injection during routine endoscopy, aligning with current EoE management guidelines.

• Clinical data show symptom and histologic improvement, strong tolerability, and durability.

• Five patent families granted globally, with expiries ranging from the 2030s to mid-2040s.

Clinical trial results and safety

• RESOLVE trial demonstrates stable drug release for 12 months and high rates of clinical remission and tissue health improvement.

• Remission rates and reduction in eosinophil counts improve with higher doses and over time.

• No serious drug-related adverse events, oropharyngeal candidiasis, or significant changes in glucose or cortisol levels observed.

• Well-tolerated profile over 230 months of patient follow-up.